SHP626
FDA fast tracks Shire’s SHP626 nonalcoholic steatohepatitis drug
July 29, 2016Research and Development FDA, SHP626, Shire, liver fibrosis, nash, volixibat, volxibat
The Food and Drug Administration (FDA) has granted Fast Track designation to Shire’s SHP626 (volixibat) treatment for patients suffering from …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
